Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).

about

Dalbavancin for the treatment of paediatric infectious diseases.Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic.Dalbavancin treatment in a deep sternal wound MRSA infection after coronary artery bypass surgery: a case report.

P2860

Q38937430-B346FF39-283E-43A1-9572-D8DF4B56C566 Q39164161-C3D79217-5ECB-46E6-8507-3616CC69B5CF Q48301411-3D172270-5A0F-4CCD-923B-227E2199260A

P2860

Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).

Item

http://www.wikidata.org/entity/Q40746046

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Dalbavancin Activity When Test ...... Six Continents (2011 to 2014).

@en

type

Item

label

Dalbavancin Activity When Test ...... Six Continents (2011 to 2014).

@en

prefLabel

Dalbavancin Activity When Test ...... Six Continents (2011 to 2014).

@en

P1476

Dalbavancin Activity When Test ...... Six Continents (2011 to 2014).

@en

P2093

Jason E Schuchert

http://www.w3.org/2001/XMLSchema#string

Rodrigo E Mendes

http://www.w3.org/2001/XMLSchema#string

Ronald N Jones

http://www.w3.org/2001/XMLSchema#string

P2860

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Once-weekly dalbavancin versus daily conventional therapy for skin infection.

Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program.

Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms.

Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States

In vivo pharmacodynamic activity of the glycopeptide dalbavancin

Origin, structure, and activity in vitro and in vivo of dalbavancin.

Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent.

A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.

P304

3419-3425

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00116-16

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27001811

http://www.w3.org/2001/XMLSchema#string

P932

4879423

http://www.w3.org/2001/XMLSchema#string

Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).

about

P2860

P2860

Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932